Antibody-drug conjugates represent a promising class of targeted cancer therapies, offering the potential for highly selective treatment with minimal off-target effects. This approach combines the precision of monoclonal antibodies with the potency of cytotoxic agents, but their success relies heavily on effective target discovery, biomarker validation, and optimized development strategies. Innovative solutions are required to address challenges related to linker stability, payload release, and tumor selectivity. This session will explore the comprehensive services available to support ADC development, including cutting-edge technologies for target identification, clinical biomarker validation, and enhancing the overall therapeutic index for safer and more effective treatments.